文献速递白血病淋巴瘤

慢性髓性白血病青少年与儿童、成人及BCR::ABL1阳性急性淋巴细胞白血病的体细胞突变与结局比较

Somatic mutations and outcomes in chronic myeloid leukemia adolescent and young adults compared to children, adults, and BCR::ABL1-positive acute lymphoblastic leukemia.
PubMed 文献 · Leukemia · 2025-04-28

这项真实世界研究比较了80例青少年、97例成人及16例儿童慢性髓性白血病慢性期(CML-CP)患者与81例BCR::ABL1阳性急性淋巴细胞白血病(Ph+ ALL)患者的突变谱及其对结局的影响。青少年CML-CP的癌症相关基因突变频率(25.0%)高于成人(19.6%)和儿童(12.5%);ASXL1突变与青少年及成人无进展生存期(PFS)缩短相关;尼洛替尼改善了携带ASXL1突变的青少年PFS。尽管突变负荷更高,青少年预后并未比成人更差。

要点

  • 青少年CML-CP的癌症相关基因突变频率为25.0%,高于成人19.6%和儿童12.5%。
  • ASXL1突变与青少年及成人CML-CP患者PFS缩短相关。
  • 尼洛替尼改善了携带ASXL1突变的青少年CML-CP患者的PFS。

核心结论

  • 尽管青少年CML-CP患者的突变负荷高于成人,但其预后并未比成人更差。
  • ASXL1突变与青少年及成人CML-CP患者PFS缩短相关,尼洛替尼改善了携带ASXL1突变的青少年患者的PFS。
  • 突变谱分析和优化TKI使用对降低携带癌症相关基因突变患者的进展风险至关重要。

研究设计与样本

  • 真实世界研究,比较80例青少年、97例成人及16例儿童CML-CP患者,以及81例Ph+ ALL患者的突变谱及其对结局的影响。

主要发现

  • 癌症相关基因突变在青少年CML-CP中更常见(25.0%),高于成人(19.6%)和儿童(12.5%)。
  • 青少年Ph+ ALL患者的突变频率(53.3%)高于儿童(26.7%)和成人(38.9%)。
  • 初诊时CML-CP以ASXL1、DNMT3A和TET2突变为主,Ph+ ALL以RUNX1、IKZF1和BCR::ABL1突变为主。
  • ASXL1突变与青少年及成人CML-CP患者PFS缩短相关。
  • 与成人不同,青少年CML-CP患者在TKI治疗期间未见BCR::ABL1激酶域突变增加。

临床怎么用

  • 作者认为,突变谱分析和优化TKI使用对降低携带癌症相关基因突变患者的进展风险至关重要。

局限性

  • ASXL1突变损害红细胞生成的发现需进一步验证。
  • 随访时突变率较低提示尼洛替尼的潜在影响,原文未进一步明确该推断的确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adolescent and young adults (AYAs) with chronic myeloid leukemia in chronic phase (CML-CP) reportedly respond worse to tyrosine kinase inhibitors (TKIs) than adults, potentially due to additional genetic abnormalities, including mutations in cancer-related genes (CRGs). This real-life study compared mutation profiles and their impact on outcomes in 80 AYA, 97 adult, and 16 pediatric CML-CP patients, alongside 81 BCR::ABL1-positive acute lymphoblastic leukemia (Ph+ ALL) patients. CRG mutations were more frequent in AYAs (25.0%) than in adults (19.6%) or children (12.5%). AYAs with Ph+ ALL exhibited higher mutational frequencies (53.3%) compared to children (26.7%) and adults (38.9%). At diagnosis, mutations in ASXL1, DNMT3A, and TET2 dominated in CML-CP and RUNX1, IKZF1, and BCR::ABL1 in Ph+ ALL. ASXL1 mutations correlated with reduced progression-free survival (PFS) in AYAs and adults. Unlike adults, AYAs showed no increase in BCR::ABL1 kinase domain mutations during TKI therapy. Nilotinib improved PFS in AYAs with ASXL1 mutations, highlighting the efficacy of higher-generation TKIs. ASXL1 mutations also impaired erythropoiesis, warranting further validation. Despite a higher mutational burden, AYAs did not exhibit worse prognoses than adults. Lower mutation rates at follow-up suggest potential impact of nilotinib. Mutation profiling and optimized TKI use are crucial to mitigate progression risks in CRG-mutated patients.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Krizkova J, Polivkova V, Laznicka A, et al. Somatic mutations and outcomes in chronic myeloid leukemia adolescent and young adults compared to children, adults, and BCR::ABL1-positive acute lymphoblastic leukemia. Leukemia. 2025. PMID: 40295826. doi:10.1038/s41375-025-02609-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。